LIFMIOR

This brand name is authorized in Austria, Estonia, Ireland, Lithuania, Poland

Active ingredients

The drug LIFMIOR contains one active pharmaceutical ingredient (API):

1 Etanercept UNII OP401G7OJC - ETANERCEPT

Etanercept is a competitive inhibitor of TNF binding to its cell surface receptors, and thereby inhibits the biological activity of TNF. The mechanism of action of etanercept is thought to be its competitive inhibition of TNF binding to cell surface TNFR, preventing TNF-mediated cellular responses by rendering TNF biologically inactive. Read about Etanercept

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L04AB01	Etanercept	L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AB Tumor necrosis factor alpha (TNF-α) inhibitors
Discover more medicines within L04AB01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1739303, 1739314, 1739325, 1739336, 1739347, 1739358, 1739369, 1739370, 1739381, 1739392, 1739404, 1739415, 1739426
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1082337, 1082338, 1082339, 1082340, 1082341, 1082342, 1082343, 1082344, 1082345, 1082346, 1082347, 1082348, 1082349
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100388047, 100388053, 100388060, 100388076